A structured approach for assessing the current status, identifying opportunities, and formulating strategies for implementing the mission of UWCCC ensures effective and well-coordinated use of Core Grant resources, institutional discretionary support and philanthropic funds. Through UWCCC program evaluation and planning efforts, a number of reviews, evaluations and retreats during the current grant period have resulted in strategic initiatives for UWCCC Scientific Programs and Shared Resources, organization and infrastructure support for Administration, focused enhancements to the Cancer Service Line, regional clinical plans and activities and Community Advisory Board priorities. These have occurred through regular strategic planning meetings of individual focus groups/committees of the Cancer Service Line;the UWCCC Community Advisory Board;the UWCCC Executive Committee, Leadership Group and EAB;and the annual UWCCC scientific retreat, as well as ad hoc review groups evaluating focused areas such as administrative organization, cancer control, research imaging, genetics and informatics. Engaging critical review by peers is an important component of evaluation and forms the basis for planning that will focus future directions. The Director, with the advice of the Executive Committee, manages all planning and development money centrally in order to maintain the ability to account for its expenditure and evaluate its impact.

Public Health Relevance

The UW Carbone Cancer Center has a well-established planning and evaluation process which includes an External Advisory Board, yearly retreats, and regular Scientific Program meetings to assure that the UWCCC is addressing the mission of the National Cancer Institute.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-40
Application #
8762780
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
40
Fiscal Year
2014
Total Cost
$105,903
Indirect Cost
$59,442
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Erbe, Amy K; Wang, Wei; Carmichael, Lakeesha et al. (2018) Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res 24:189-196
Eckers, Jaimee C; Swick, Adam D; Kimple, Randall J (2018) Identity Crisis - Rigor and Reproducibility in Human Cell Lines. Radiat Res 189:551-552
Zahm, Christopher D; Colluru, Viswa T; McIlwain, Sean J et al. (2018) TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8+ T Cells. Cancer Immunol Res 6:1364-1374
Chen, Feng; Goel, Shreya; Shi, Sixiang et al. (2018) General synthesis of silica-based yolk/shell hybrid nanomaterials and in vivo tumor vasculature targeting. Nano Res 11:4890-4904
Schwei, Rebecca J; Schroeder, Michelle; Ejebe, Ifna et al. (2018) Limited English Proficient Patients' Perceptions of when Interpreters are Needed and how the Decision to Utilize Interpreters is Made. Health Commun 33:1503-1508
Nyman, Patrick E; Buehler, Darya; Lambert, Paul F (2018) Loss of Function of Canonical Notch Signaling Drives Head and Neck Carcinogenesis. Clin Cancer Res 24:6308-6318
O'Driscoll, Chelsea A; Owens, Leah A; Gallo, Madeline E et al. (2018) Differential effects of diesel exhaust particles on T cell differentiation and autoimmune disease. Part Fibre Toxicol 15:35
Fleszar, Andrew J; Walker, Alyssa; Porubsky, Veronica et al. (2018) The Extracellular Matrix of Ovarian Cortical Inclusion Cysts Modulates Invasion of Fallopian Tube Epithelial Cells. APL Bioeng 2:
Tucholka, Jennifer L; Yang, Dou-Yan; Bruce, Jordan G et al. (2018) A Randomized Controlled Trial Evaluating the Impact of Web-Based Information on Breast Cancer Patients' Knowledge of Surgical Treatment Options. J Am Coll Surg 226:126-133
Thomas, Sydney P; Hoang, Trish T; Ressler, Valerie T et al. (2018) Human angiogenin is a potent cytotoxin in the absence of ribonuclease inhibitor. RNA 24:1018-1027

Showing the most recent 10 out of 1528 publications